凝血纤溶系统标志物动态变化在冠状动脉粥样硬化性心脏病的应用研究  

Clinical value of the dynamic monitoring of blood coagulation and fibrinolysis system in coronary atherosclerotic heart disease

作　　者：林伟华 何艳 黄秀红 陈华英 朱彩兰 

机构地区：[1]广东省湛江市中心人民医院临床检验中心,524037 [2]广东省湛江市中心人民医院心内科,524037

出　　处：《国际检验医学杂志》2011年第12期1279-1280,共2页International Journal of Laboratory Medicine

基　　金：湛江市科技计划项目(2010c3115001)

摘　　要：目的探讨凝血纤溶系统的动态变化监测在冠状动脉粥样硬化性心脏病(CAHD)诊断和治疗中的应用价值。方法采用发色底物法对152例CAHD患者(CAHD组)及40例健康对照者(对照组)血浆抗凝血酶Ⅲ(ATⅢ)、蛋白C(PC)、纤溶酶原激活物抑制物-1(PAI-1)、凝血酶激活的纤溶抑制物活性(TAFI:A)水平进行检测。结果与对照组比较,CAHD组患者治疗前血浆ATⅢ、PC水平明显降低(P<0.05),PAI-1、TAFI:A水平明显升高(P<0.05);CAHD组患者治疗后,仅血浆PC水平与对照组比较差异有统计学意义(P<0.05)。结论血浆ATⅢ、PC、PAI-1、TAFI:A水平检测应用于CAHD的诊断和治疗具有一定的临床意义。Objective To explore the clinical value of the dynamic monitoring of blood coagulation and fibrinolysis system for the diagnosis and therapy of coronary atherosclerotic heart disease（CAHD）.Methods 152 cases of patients with CAHD（CAHD group） and 40 healthy controls（control group） were enrolled and detected for the plasma levels of antithrombin Ⅲ（ATⅢ）,protein C（PC）,plasminogen activator inhibitor-1（PAI-1） and thrombin-activatable fibrinolysis inhibitor：activity（TAFI：A）.Results Plasma levels of ATⅢ and PC in CAHD group,before being treated,were lower than control group（P〈0.05）,and those of PAI-1 and TAFI：A were higher than control group（P〈0.05）.After therapy,only plasma level of PC in CAHD group was lower than control group（P〈0.05）.Conclusion The detection of plasma level of ATⅢ,PC,PAI-1 and TAFI：A could have certain clinical value for the diagnosis of the diagnosis and therapy of CAHD

关 键 词：冠心病 血液凝固 纤溶酶原灭活剂 抗凝血酶Ⅲ 

分 类 号：R541.4[医药卫生—心血管疾病]